Bone Morphogenetic Protein Market Size by Application, Type, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2029
Overview
Bone Morphogenetic Protein Market size is expected to grow at a CAGR of 2.90% during the forecast period and the market size is expected to reach nearly US$ 745.80 Million by 2029.
The global Bone Morphogenetic Protein market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Bone Morphogenetic Protein report also provides trends by market segments, technology, and investment with a competitive landscape. 
To know about the Research Methodology :- Request Free Sample Report
Bone Morphogenetic Protein Market Overview:
BMPs (bone morphogenetic proteins) are a group of naturally occurring proteins that play a role in tissue formation and growth. BMPs are active in tissues other than bone, despite their name. BMP promotes the creation of new bone in the body. The majority of bone morphogenetic proteins (BMPs) are members of the Transforming Growth Factor (TGF) family of proteins. BMPs play a significant role in the development of bone and cartilage, as well as embryogenesis. The most advanced commercial clinical application of BMP has been in spinal fusion surgery products for both lumbar and cervical spine indications.
Covid-19 impact on Bone Morphogenetic Protein Market:
The global effects of the coronavirus disease 2019 (COVID-19) are already being felt, and the demand for Bone Morphogenetic Protein (BMP) 2 will be significantly impacted in 2020. COVID-19 has the potential to have three major effects on the global economy: directly influencing production and demand, causing supply chain and consumer instability, and having a financial impact on businesses and financial markets.
Bone Morphogenetic Protein Market Dynamics:
The importance of bone morphogenetic proteins in medical procedures has improved market prospects. rhBMP-2 and rhBMP-7, two main bone morphogenetic proteins, have recently gained notoriety. The FDA's approvals have considerably contributed to the popularity of bone morphogenetic proteins. Both metabologens and cytokines are bone morphogenetic proteins, and medical research on the former is gaining momentum. The existence of bone morphogenetic proteins influences the body's tissue architecture. This, together with advances in osteopathy, has fueled the market growth. Physiology has attracted the attention of several research schools and scientists.
In the global market, the role of bone morphogenetic proteins in physiological research has become a significant demand factor. In the medical community, pathological processes have gained a lot of momentum, which is important for business expansion. The misregulation of bone morphogenetic proteins (BMPs) can be fatal to those who are affected. The global demand for bone morphogenetic proteins has increased significantly as a result of this factor.
Biocompatibility risks, rising prices, and the availability of alternative products namely bone grafts, scaffolds, and others may all hinder the global bone morphogenetic protein market's development.
Bone Morphogenetic Protein Market Segment Analysis:
Based on Type, the rhBMP-2 protein sub-segment is expected to hold the largest global bone morphogenetic proteins market share. It may happen as a result of the high rate of doctors and surgeons adopting and using the rhBMP-2 protein as a result of the high number of sports injuries.
Based on the Application, the Spinal Fusion segment is expected to hold the largest market size during the forecast period. In spinal fusion surgery, bone morphogenetic protein (BMP) is a protein that facilitates bone formation in the body. BMP is generally known for promoting fusion at a faster rate than traditional bone graft surgery, according to studies. As a result, BMP makes it easier for the surgeon to perform the procedure, resulting in a higher fusion rate and avoiding the risks associated with iliac crest autograft (hip) graft harvest. The surgical time is cut in half and complication rates are lower when the hip graft is avoided, resulting in a quicker and less painful recovery. The use of BMP in spinal fusion surgery is increasing as the number of spinal operations increases and the ease of surgery with BMP improves.
Bone Morphogenetic Protein Market Regional Insights:
North America currently holds the majority of the industry and is expected to do so for a few more years. The growth of the market in this area is primarily due to a well-established healthcare system, the rapid adoption of Infuse bone morphogenetic protein, increased demand for bone growth stimulators, and the adoption of novel technologies in the region. The protein molecule rhBMP-2 was approved by the US FDA and has since become one of the most common procedures for bone surgeries in the US.
According to the National Spinal Cord Injury Statistical Center, nearly 17,730 cases of spinal cord injuries occur annually in the United States in 2019, indicating that the use of bone morphogenetic proteins in the country have a lot of potentials. The demand for bone morphogenetic proteins are expected to grow in Europe over the forecast period, owing to a rise in the incidence of spinal injuries and the number of orthopedic surgeries.
Due to an increase in the number of standalone orthopedic clinics and increased knowledge of innovative products and treatments, Asia Pacific is projected to expand at a rapid pace during the forecast era.
The objective of the report is to present a comprehensive analysis of the global Bone Morphogenetic Protein market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the global Bone Morphogenetic Protein market dynamics, structure by analyzing the market segments and project the global Bone Morphogenetic Protein market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global Bone Morphogenetic Protein market make the report investor’s guide.
Bone Morphogenetic Protein Market Key Developments:
In September 2019, Medtronic, an Irish medical device firm, announced that it had secured FDA clearance for pivotal, randomized, and prospective clinical trials for the use of Infuse bone graft. The results of the research would enable bone graft to be used in Transforaminal Lumbar Interbody Fusion (TLIF) spine procedures. TLIF is a form of surgery that uses a posterior approach to connect or fuse spinal bones.
Bone Morphogenetic Protein Market Scope:Inquire before buying
| Global Bone Morphogenetic Protein Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 610.54 Mn. |
| Forecast Period 2023 to 2029 CAGR: | 2.9% | Market Size in 2029: | US $ 745.80 Mn. |
| Segments Covered: | by Application | Spinal Fusion Trauma Surgery Reconstruction Surgery Oral Maxillofacial Surgery Others |
|
| by Type | rhBMP-2 rhBMP-7 Others |
||
Bone Morphogenetic Protein Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Bone Morphogenetic Protein Market Key Players
1. Medtronic
2. Cellumed Co. Ltd.
3. Stryker
4. Sigma Aldrich Co.
5. ProSpec
6. Ember Therapeutics
7. R&D Systems
8. Thermo Fisher Scientific, Inc.
9. DePuy Synthes
10.Nuvasive, Inc.
11.Orthofix Holdings, Inc.
12.Smith and Nephew, Inc.
13.Wright Medical Group N.V.
14.Other Key Players
Frequently Asked Questions:
1. Which region has the largest share in Global Bone Morphogenetic Protein Market?
Ans: North America region holds the highest share in 2022.
2. What is the growth rate of Global Bone Morphogenetic Protein Market?
Ans: The Global Market is growing at a CAGR of 2.90% during forecasting period 2023-2029.
3. What is scope of the Global Bone Morphogenetic Protein market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global market?
Ans: The important key players in the Global Market are – Medtronic, Cellumed Co. Ltd., Stryker, Sigma Aldrich Co., ProSpec, Ember Therapeutics, R&D Systems, Thermo Fisher Scientific, Inc., DePuy Synthes, Nuvasive, Inc., Orthofix Holdings, Inc., Smith and Nephew, and Inc.
5. What is the study period of this market?
Ans: The Global Market is studied from 2022 to 2029.